



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 MADRID

Granada, 23 September 2015

RELEVANT FACT OF NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by companies in expansion integrated in the MAB, we hereby puts in knowledge that the Spanish Patents and Trademarks Office (SPTO) has granted Neuron Bio, S.A. with the patent “Neuroprotective, anti-inflammatory and antiepileptic compounds” published in the Spanish Official Bulletin of Industrial Property with number ES 2 524 647 B1.

This patent protects the use of the compounds, which are internally named NST0076 and NST0078 and have been selected for their anti-inflammatory neuroprotective and antiepileptic capacities. The compounds are potentially effective as treatment for neurodegenerative diseases or disorders of the nervous system, concretely for its application in the Alzheimer’s disease and epilepsy.

Press release is enclosed.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Press release

Neuron Bio patents two new molecules that enter more efficiently into the brain and avoid neuronal death

Granada, 23 September 2015. The Spanish Patent and Trademark Office (SPTO) has granted Neuron Bio with a patent for two compounds that protect neuronal death and penetrate with high efficiency into the brain, two essential features to be used as treatments that delay the start of Alzheimer's disease and other neurodegenerative disorders.

The patent protects the use of the compounds, which are internally named NST0076 and NST0078 and have been selected for their anti-inflammatory neuroprotective and antiepileptic capacities. The compounds are potentially effective as treatment for neurodegenerative diseases or disorders of the nervous system, concretely for its application in the Alzheimer's disease and epilepsy.

Javier Burgos, CEO of the company has made a very positive appraisal of this news and stated, "These compounds have been developed thanks to the expertise accumulated by the researchers of the company after evaluating thousands of potential candidates, using company's own exclusive drug discovery platform that includes models of this disease in human cells and animal models."



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

For further information:

Malena Valdivieso
mvaldivieso@neuronbio.com
Tel.: +34 958 750 598
www.neuronbio.com

Note for editors:
About Neuron Bio

Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas.

Its **pharma division** is mainly devoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer's disease.

Its **diagnostic division** develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as the Alzheimer's disease.

Its **service division** develops research projects as well as consultancy services for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area.

Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 9 patent applications (2 of them recently granted by the European Union and other 1 also granted by the US Patent and Trademark Office) and exclusive platforms for drug discovery and development.

Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

It has a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects.

Neuron Bio has facilities in Granada and Madrid connected with university research centers and is quoted on the Alternative Stock Market (MAB) in Spain.